Icad INC Form 4 insider transactions

RadNet intends to acquire iCAD to integrate its breast AI technology into DeepHealth's portfolio, enhancing early detection and diagnosis of breast cancer.

RadNet plans to acquire iCAD for approximately $103 million, aiming to integrate iCAD's AI solutions into DeepHealth to improve breast cancer detection.

RadNet plans to acquire iCAD, aiming to create a comprehensive portfolio of diagnostic AI, personalized risk assessment, and integrated viewing and reporting tools, with the transaction expected to close in the second or third quarter of 2025.

RadNet announces its intent to acquire iCAD, integrating its AI solutions into DeepHealth's portfolio to improve breast cancer detection and diagnosis globally.

RadNet, Inc. has announced its plan to acquire iCAD, Inc., with details disclosed in a LinkedIn post and forthcoming SEC filings.

RadNet's subsidiary, DeepHealth, is set to acquire iCAD, signaling a strategic expansion in the medical imaging AI space.

RadNet, Inc. is set to acquire iCAD, Inc. in an all-stock transaction valued at approximately $103 million, with the goal of enhancing its DeepHealth portfolio and expanding its AI-powered solutions in breast health.

RadNet announces its plan to acquire iCAD, a leader in AI-powered breast health solutions, to enhance capabilities and expand reach in early breast cancer detection.

RadNet has announced the acquisition of iCAD and released internal communications guidelines to DeepHealth employees.

RadNet, Inc. announces its intent to acquire iCAD, Inc., aiming to create a comprehensive portfolio of diagnostic AI and imaging solutions, with the transaction expected to close in the second or third quarter of 2025.

RadNet plans to acquire iCAD, with details to be disclosed in upcoming SEC filings.

RadNet plans to acquire iCAD, with both companies filing documents with the SEC regarding the proposed transaction.

RadNet, Inc. is set to acquire iCAD, Inc. in an all-stock transaction valued at approximately $103 million, with the goal of creating a comprehensive portfolio of breast screening AI and integrated tools.

RadNet will acquire iCAD in an all-stock transaction valued at approximately $103 million, combining their AI-powered breast cancer detection and workflow solutions.

Dana R Brown, a Director and Officer of ICAD INC, reports the acquisition of 25,833 bonus shares of common stock on February 21, 2025, in lieu of a cash bonus.

Eric Lonnqvist, CFO of ICAD Inc., received 15,833 shares of common stock as a bonus in lieu of cash for the fiscal year 2024.

Susan Alyson Wood, a director of ICAD INC, acquired 10,593 stock options on February 5, 2025, in lieu of quarterly cash director fees.

Director Hedvig Hricak acquired 6,641 stock options in ICAD INC on February 5, 2025, in lieu of quarterly cash director fees.

Director Michael Doyle reports the acquisition of stock options in ICAD INC in lieu of quarterly cash director fees.

Director Rakesh Patel receives stock options in ICAD INC in lieu of quarterly cash director fees, according to a Form 4 filing.

Director Hedvig Hricak of ICAD Inc. has acquired 30,000 stock options, exercisable at $2.06, which vest quarterly over a 12-month period.

Director Rakesh Patel of ICAD Inc. reported the acquisition of 30,000 stock options on January 3, 2025.

Director Andy Sassine of ICAD Inc. was granted 30,000 stock options on January 3, 2025, which vest quarterly over a 12-month period.

ICAD Inc. director Susan Alyson Wood was granted 30,000 stock options on January 3, 2025, which vest quarterly over a 12-month period.

ICAD Inc. director Michael Doyle was granted 30,000 stock options on January 3, 2025, which vest quarterly over a twelve-month period.

Director Andy Sassine acquired 27,586 stock options in ICAD Inc. on August 15, 2024, in lieu of quarterly cash director fees.

Director Rakesh Patel acquired 24,194 stock options in ICAD INC on August 15, 2024, in lieu of quarterly cash director fees.

Director Susan Alyson Wood acquired 13,044 stock options in ICAD INC on April 1, 2024, in lieu of quarterly cash director fees.

Director Rakesh Patel acquired 22,154 stock options in ICAD INC on April 1, 2024, in lieu of quarterly cash director fees.

Director Michael Doyle acquired 9,874 stock options in ICAD Inc. in lieu of quarterly cash director fees on April 1, 2024.